Effect of daily intake of a low-alcohol orange beverage on cardiovascular risk factors in hypercholesterolemic humans.

Journal: Food research international (Ottawa, Ont.)
PMID:

Abstract

Oxidative stress, inflammation status, endothelial dysfunction, and imbalanced lipid metabolism play a major role in cardiovascular disease. Bioactive compounds and moderate alcohol consumption have been associated with decreased cardiovascular risk. This study aimed to evaluate the effect on cardiovascular risk factors of a low-alcohol beverage derived from the alcoholic fermentation of orange juice. Eighteen individuals with moderately high cholesterol levels were randomly assigned to an experimental group (n = 9) who drank 500 mL/day of the orange beverage for 2 weeks or a control group (n = 9) who drank no orange beverage. Blood samples were drawn at the beginning and end of the study period. Consumption of the beverage significantly decreased plasma levels of total cholesterol (-15.6%), LDL-cholesterol (-17.8%), LDL-cholesterol/HDL-cholesterol ratio (-21.4%), catalase (-25.5%), TBARS (-42.6%), and sVCAM-1 (-5.8%). This orange beverage would have a potential capacity to improve cardiovascular risk in hypercholesterolemic humans, supporting its future consideration as a functional beverage.

Authors

  • I Cerrillo
    Área de Nutrición y Bromatología, Departamento de Biología Molecular e Ingeniería Bioquímica, Universidad Pablo de Olavide, Ctra. Utrera Km 1, 41013 Sevilla, Spain; Investigador Asociado, Facultad de Ciencias de la Salud, Universidad Autónoma de Chile, Avda. Pedro de Valdivia 425, Providencia, Santiago de Chile, Chile. Electronic address: icergar@upo.es.
  • B Escudero-López
    Área de Nutrición y Bromatología, Departamento de Biología Molecular e Ingeniería Bioquímica, Universidad Pablo de Olavide, Ctra. Utrera Km 1, 41013 Sevilla, Spain.
  • A Ortega
    Área de Nutrición y Bromatología, Departamento de Biología Molecular e Ingeniería Bioquímica, Universidad Pablo de Olavide, Ctra. Utrera Km 1, 41013 Sevilla, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Universidad Pablo de Olavide, Sevilla, Spain.
  • F Martín
    Área de Nutrición y Bromatología, Departamento de Biología Molecular e Ingeniería Bioquímica, Universidad Pablo de Olavide, Ctra. Utrera Km 1, 41013 Sevilla, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Universidad Pablo de Olavide, Sevilla, Spain.
  • M S Fernández-Pachón
    Área de Nutrición y Bromatología, Departamento de Biología Molecular e Ingeniería Bioquímica, Universidad Pablo de Olavide, Ctra. Utrera Km 1, 41013 Sevilla, Spain; Investigador Asociado, Facultad de Ciencias de la Salud, Universidad Autónoma de Chile, Avda. Pedro de Valdivia 425, Providencia, Santiago de Chile, Chile.